2024
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study
Vitale A, Trapani S, Russo F, Miele L, Baroni G, Marchesini G, Burra P, Ottoveggio M, Romagnoli R, Martini S, De Simone P, Carrai P, Cescon M, Morelli M, De Carlis L, Belli L, Gruttadauria S, Volpes R, Colledan M, Fagiuoli S, Di Benedetto F, De Maria N, Rossi G, Caccamo L, Donato F, Vennarecci G, Di Costanzo G, Vivarelli M, Carraro A, Sacerdoti D, Ettorre G, Giannelli V, Agnes S, Gasbarrini A, Rossi M, Corradini S, Mazzaferro V, Bhoori S, Manzia T, Lenci I, Zamboni F, Mameli L, Baccarani U, Toniutto P, Lupo L, Tandoi F, Rendina M, Andorno E, Giannini E, Spada M, Billato I, Marchini A, Romano P, Brancaccio G, D’Amico F, Ricci A, Cardillo M, Cillo U, del Fegato . A, . S, Trapianti C. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study. JHEP Reports 2024, 6: 101147. PMID: 39282226, PMCID: PMC11399673, DOI: 10.1016/j.jhepr.2024.101147.Peer-Reviewed Original ResearchSurvival benefit of patientsTransplant survival benefitHepatocellular carcinomaLiver transplantationLiver diseaseIncreased waitlist mortalityPatient survivalBenefit of patientsSteatotic liver diseaseEnd-stage chronic liver diseaseAbstractText Label="Background &Waiting listImprove patient survivalWaitlist mortalityLiver transplant indicationsChronic liver diseaseAlcoholic liver diseaseRisk of deathWaiting list mortalityAbstractText Label="ImpactPrognostic featuresTransplant eligibility criteriaSurvival benefitTransplant indicationAdult patients
2021
NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management.
DI Renzo C, Vitale A, D'Amico F, Cillo U. NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. Minerva Surgery 2021, 76: 450-466. PMID: 33855376, DOI: 10.23736/s2724-5691.21.08729-0.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisNon-alcoholic steatohepatitis cirrhosisNon-alcoholic steatohepatitis patientsDegree of suspicionPost-transplant managementFatty liver diseasePatient related issuesLiver transplantationLiver diseaseEarly diagnosisMetabolic dysfunctionMorbidity spectrumComplication managementDiagnostic testsDiagnosisMetabolic issuesPatients
2012
Use of N‐acetylcysteine during liver procurement: A prospective randomized controlled study
D'Amico F, Vitale A, Piovan D, Bertacco A, Morales R, Frigo A, Bassi D, Bonsignore P, Gringeri E, Valmasoni M, Garbo G, Lodo E, D'Amico FE, Scopelliti M, Carraro A, Gambato M, Brolese A, Zanus G, Neri D, Cillo U. Use of N‐acetylcysteine during liver procurement: A prospective randomized controlled study. Liver Transplantation 2012, 19: 135-144. PMID: 22859317, DOI: 10.1002/lt.23527.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAntioxidantsChi-Square DistributionFemaleGraft SurvivalHumansInfusions, IntravenousItalyKaplan-Meier EstimateLiver TransplantationMaleMiddle AgedPortal VeinPrimary Graft DysfunctionProportional Hazards ModelsProspective StudiesSingle-Blind MethodTime FactorsTissue and Organ HarvestingTreatment OutcomeYoung AdultConceptsGraft survivalLiver transplantationNAC groupLiver procurementN-acetylcysteineControl groupSuboptimal graftsEffect of NACNAC protocolIschemia/reperfusion damageFirst liver transplantationEarly graft functionGraft survival ratesChronic liver diseaseSingle-blinded procedureGraft functionLT outcomesPostoperative complicationsPrimary endpointCox analysisNAC infusionRandomized studyLiver diseaseAdult candidatesPrimary dysfunction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply